Published in J Mol Biol on October 29, 1999
The rhodanese/Cdc25 phosphatase superfamily. Sequence-structure-function relations. EMBO Rep (2002) 1.94
Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol (2003) 1.71
A small CDC25 dual-specificity tyrosine-phosphatase isoform in Arabidopsis thaliana. Proc Natl Acad Sci U S A (2004) 1.13
Crystal structure of the human lymphoid tyrosine phosphatase catalytic domain: insights into redox regulation . Biochemistry (2009) 1.04
General library-based Monte Carlo technique enables equilibrium sampling of semi-atomistic protein models. J Phys Chem B (2009) 1.03
Mechanism of Cdc25B phosphatase with the small molecule substrate p-nitrophenyl phosphate from QM/MM-MFEP calculations. J Phys Chem B (2009) 0.96
Cdc25B functions as a novel coactivator for the steroid receptors. Mol Cell Biol (2001) 0.90
Remote hot spots mediate protein substrate recognition for the Cdc25 phosphatase. Proc Natl Acad Sci U S A (2004) 0.90
Adventitious arsenate reductase activity of the catalytic domain of the human Cdc25B and Cdc25C phosphatases. Biochemistry (2010) 0.88
Regulation of the activity of the tumor suppressor PTEN by thioredoxin in Drosophila melanogaster. Exp Cell Res (2007) 0.86
Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening. Curr Med Chem (2008) 0.83
Solution structure of the rhodanese homology domain At4g01050(175-295) from Arabidopsis thaliana. Protein Sci (2004) 0.83
Temperature dependence of binding and catalysis for the Cdc25B phosphatase. Biophys Chem (2006) 0.81
Catalytic site cysteines of thiol enzyme: sulfurtransferases. J Amino Acids (2010) 0.80
Alteration of oligomeric state and domain architecture is essential for functional transformation between transferase and hydrolase with the same scaffold. Protein Sci (2009) 0.80
Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem (2016) 0.80
Voltage sensitive phosphatases: emerging kinship to protein tyrosine phosphatases from structure-function research. Front Pharmacol (2015) 0.80
Crystallization and preliminary crystallographic characterization of LmACR2, an arsenate/antimonate reductase from Leishmania major. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.78
Identification of a C-terminal cdc25 sequence required for promotion of germinal vesicle breakdown. Biochem J (2000) 0.78
Toward the virtual screening of Cdc25A phosphatase inhibitors with the homology modeled protein structure. J Mol Model (2008) 0.77
Phosphotyrosine Substrate Sequence Motifs for Dual Specificity Phosphatases. PLoS One (2015) 0.77
Druggability analysis and classification of protein tyrosine phosphatase active sites. Drug Des Devel Ther (2016) 0.75
Structure of an E. coli integral membrane sulfurtransferase and its structural transition upon SCN(-) binding defined by EPR-based hybrid method. Sci Rep (2016) 0.75
Macromolecular Crystallographic Information File. Methods Enzymol (1997) 11.94
Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature (1990) 3.81
NH---S hydrogen bonds in Peptococcus aerogenes ferredoxin, Clostridium pasteurianum rubredoxin, and Chromatium high potential iron protein. Proc Natl Acad Sci U S A (1975) 1.91
Cation binding to the integrin CD11b I domain and activation model assessment. Structure (1998) 1.90
Water structure in a protein crystal: rubredoxin at 1.2 A resolution. J Mol Biol (1978) 1.89
Crystallographic refinement of rubredoxin at 1 x 2 A degrees resolution. J Mol Biol (1980) 1.85
The structure of a non-heme iron protein: rubredoxin at 1.5 Angstrom resolution. Cold Spring Harb Symp Quant Biol (1972) 1.67
The Hsp56 component of steroid receptor complexes binds to immobilized FK506 and shows homology to FKBP-12 and FKBP-13. J Biol Chem (1992) 1.63
Heat shock protein induction in rat hearts. A role for improved myocardial salvage after ischemia and reperfusion? Circulation (1992) 1.57
The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem (1992) 1.55
The atomic-resolution structure of human caspase-8, a key activator of apoptosis. Structure (1999) 1.54
Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol (1997) 1.52
Heat-shock protein induction in rat hearts. A direct correlation between the amount of heat-shock protein induced and the degree of myocardial protection. Circulation (1994) 1.49
The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor. J Biol Chem (1995) 1.48
Absorption, excretion and half-life of clinimycin in normal adult males. Am J Med Sci (1968) 1.48
Structure of the oxidized form of a flavodoxin at 2.5-Angstrom resolution: resolution of the phase ambiguity by anomalous scattering. Proc Natl Acad Sci U S A (1972) 1.47
Crystal structure of recombinant human interleukin-1 beta at 2.0 A resolution. J Mol Biol (1989) 1.46
Comparison of the crystal structures of a flavodoxin in its three oxidation states at cryogenic temperatures. J Mol Biol (1991) 1.44
Developing the accredited postgraduate assessment program for Fellowship of the Australian College of Rural and Remote Medicine. Rural Remote Health (2007) 1.43
The structure of rubredoxin at 1.2 A resolution. J Mol Biol (1979) 1.38
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem (1998) 1.29
The binding of riboflavin-5'-phosphate in a flavoprotein: flavodoxin at 2.0-Angstrom resolution. Proc Natl Acad Sci U S A (1973) 1.26
Overexpression of heat shock protein 72 in transgenic mice decreases infarct size in vivo. Circulation (1996) 1.26
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1996) 1.24
Modulation of Ia-like antigen expression and antigen-presenting activity of human monocytes by endotoxin and zymosan A. J Immunol (1981) 1.20
Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation (1989) 1.18
Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. J Biol Chem (1991) 1.16
Characterization of the protein-protein interactions determining the heat shock protein (hsp90.hsp70.hsp56) heterocomplex. J Biol Chem (1994) 1.14
Pulmonary hypertension associated with liver disease is not reversible after liver transplantation. Anesthesiology (1992) 1.12
Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1994) 1.09
Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. J Biol Chem (1992) 1.08
The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J Biol Chem (2001) 1.08
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. J Med Chem (1997) 1.06
A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that is enzymatically active. J Biol Chem (1991) 1.04
Cytoplasmic and mitochondrial tRNA nucleotidyltransferase activities are derived from the same gene in the yeast Saccharomyces cerevisiae. J Biol Chem (1992) 1.03
Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J Biol Chem (1993) 1.03
FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. J Biol Chem (1993) 1.03
Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation (1997) 1.01
The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J Biol Chem (1993) 1.01
FK506 binding to the 56-kilodalton immunophilin (Hsp56) in the glucocorticoid receptor heterocomplex has no effect on receptor folding or function. Biochemistry (1993) 1.00
Purification of a high molecular weight human terminal deoxynucleotidyl transferase. J Biol Chem (1979) 0.98
The structure and absolute configuration of pentalenolactone (PA 132). Tetrahedron Lett (1970) 0.97
Exposure to environmental tobacco smoke increases myocardial infarct size in rats. Circulation (1994) 0.96
The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase. J Biol Chem (1993) 0.96
Right ventricular infarction: recognition and assessment of its hemodynamic significance by two-dimensional echocardiography. J Am Soc Echocardiogr (1991) 0.94
The crystal structure of a lysine 49 phospholipase A2 from the venom of the cottonmouth snake at 2.0-A resolution. J Biol Chem (1990) 0.94
Biochemical properties of purified human terminal deoxynucleotidyltransferase. J Biol Chem (1980) 0.94
Tissue distribution and cellular localization of hsp56, an FK506-binding protein. Characterization using a highly specific polyclonal antibody. J Biol Chem (1992) 0.93
The hsp56 immunophilin component of untransformed steroid receptor complexes is localized both to microtubules in the cytoplasm and to the same nonrandom regions within the nucleus as the steroid receptor. Mol Endocrinol (1994) 0.92
Ischemic preconditioning attenuates ischemia/reperfusion-induced activation of caspases and subsequent cleavage of poly(ADP-ribose) polymerase in rat hearts in vivo. Cardiovasc Res (1999) 0.92
The native v-Raf.hsp90.p50 heterocomplex contains a novel immunophilin of the FK506 binding class. J Biol Chem (1994) 0.92
Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E. Biochemistry (1993) 0.91
Recombinant human interleukin-1 alpha and recombinant human interleukin-1 beta stimulate cartilage matrix degradation and inhibit glycosaminoglycan synthesis. Inflammation (1989) 0.90
Preconditioning ischemia time determines the degree of glycogen depletion and infarct size reduction in rat hearts. Am Heart J (1996) 0.88
Expression of terminal deoxynucleotidyl transferase in human thymus during ontogeny and development. J Immunol (1983) 0.88
Site-specific chemical modification of interleukin-1 beta by acrylodan at cysteine 8 and lysine 103. J Biol Chem (1992) 0.88
Quantification of myocardial infarction: a comparison of single photon-emission computed tomography with pyrophosphate to serial plasma MB-creatine kinase measurements. Circulation (1985) 0.87
A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochem Biophys Res Commun (1999) 0.87
The isolation, structure, and absolute configuration of U-43,795, a new antitumor agent. J Antibiot (Tokyo) (1975) 0.87
Cholinergic activity of acetylenic imidazoles and related compounds. J Med Chem (1991) 0.87
Limited proteolysis of calf thymus terminal deoxynucleotidyl transferase. Arch Biochem Biophys (1980) 0.86
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors. J Med Chem (1996) 0.86
An active FK506-binding domain of 17,000 daltons is isolated following limited proteolysis of chicken thymus hsp56. Biochemistry (1993) 0.85
12-lead ST-segment monitoring vs single-lead maximum ST-segment monitoring for detecting ongoing ischemia in patients with unstable coronary syndromes. Am J Crit Care (1998) 0.84
Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful? Cardiol Clin (1994) 0.84
Catalase inhibition with 3-amino-1,2,4-triazole does not abolish infarct size reduction in heat-shocked rats. Circulation (1995) 0.84
Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg Med Chem Lett (2001) 0.83
Thrombolysis after acute myocardial infarction. Who should be added to inclusion criteria? Postgrad Med (1994) 0.83
Tryptophan fluorescence of terminal deoxynucleotidyl transferase: effects of quenchers on time-resolved emission spectra. Biochemistry (1985) 0.83
A two step purification of recombinant human interleukin-1 beta expressed in E. coli. Immunol Invest (1989) 0.82
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation (1996) 0.82
Purification and characterization of invertase from a novel industrial yeast, Schwanniomyces occidentalis. Prep Biochem (1989) 0.82
A model of acute regional myocardial ischemia and reperfusion in the rat. Magn Reson Med (1989) 0.82
Escherichia coli expression and processing of human interleukin-1 beta fused to signal peptides. DNA Cell Biol (1990) 0.82
Overview of phasing by isomorphous replacement. Methods Enzymol (1985) 0.81
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives. J Med Chem (1993) 0.81
Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors. J Med Chem (1996) 0.81
Structure of CC-1065 (NSC-298223), a new antitumor antibiotic. J Antibiot (Tokyo) (1980) 0.81
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors. J Med Chem (1995) 0.81
Structures and comparison of the Y98H (2.0 A) and Y98W (1.5 A) mutants of flavodoxin (Desulfovibrio vulgaris). Acta Crystallogr D Biol Crystallogr (2001) 0.80
The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochem Pharmacol (1996) 0.80
12,13-isotaxanes: synthesis of new potent analogs and X-ray crystallographic confirmation of structure. J Med Chem (1997) 0.80
Resolution of two deoxynucleoside kinases from Lactobacillus acidophilus R-26 by Blue Sepharose affinity chromatography. J Biol Chem (1977) 0.80
Is the reduction of myocardial infarct size by dietary fish oil the result of altered platelet function? Am Heart J (1994) 0.80
Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol (1994) 0.80
On-resin biotinylation of chemically synthesized proteins for one-step purification. Anal Biochem (1988) 0.80
Biochemical and immunological properties of human terminal deoxynucleotidyl transferase purified from blasts of acute lymphoblastic and chronic myelogenous leukemia. J Clin Invest (1981) 0.79
Structure-activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors. Bioorg Med Chem (2000) 0.79
Acute myocardial ischemia and reperfusion: MR imaging with albumin-Gd-DTPA. Radiology (1989) 0.79
Frequency, duration, magnitude, and consequences of myocardial ischemia during intracoronary ultrasonography. Am Heart J (1997) 0.79
Cis reduction of 24 of lanosterol in the biosynthesis of cholesterol by rat liver enzymes. A revision. J Am Chem Soc (1971) 0.79
L-arginine decreases infarct size in rats exposed to environmental tobacco smoke. Am Heart J (1996) 0.78
Pyrimidine and triazine 3-oxide sulfates: a new family of vasodilators. J Med Chem (1983) 0.78